Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Endocrine Disorders
Published in: BMC Endocrine Disorders 1/2023

Open Access 01-12-2023 | Hashimoto Thyroiditis | Research

The evaluation of locoregional tumoral involvement in the cooccurrence of hashimoto thyroiditis with papillary thyroid cancer: a case controlled study

Authors: Shirzad Nasiri, Seyed Mostafa Meshkati Yazd, Mahsa Gholami, Sepehr Shahriarirad, Sina Sharghi, Reza Shahriarirad

Published in: BMC Endocrine Disorders | Issue 1/2023

Login to get access

Abstract

Background

Papillary thyroid carcinoma PTC is the most prevalent of all thyroid carcinomas. On the other hand, Hashimoto’s thyroiditis (HT), as part of the spectrum of autoimmune thyroid diseases, is a major cause of thyroid hypofunction worldwide. Several studies have aimed to indicate a possible correlation between PTC and HT over the years. This study aims to investigate the correlation between HT disease and PTC tumor invasion rate.

Method

In the present cross-sectional study, PTC patients with HT were selected among patients referred to the surgical ward of Shariati hospital from 2016 to 2019 and compared in terms of tumor invasion and central LN dissection. Also, a similar group of PTC patients without HT undergoing total thyroidectomy was selected for comparison. The tumor invasion rate was assessed based on invasion indices obtained from postoperative permanent pathology specimens. These indices included tumor type and size, number of involved LNs, lymphovascular involvement, perineural involvement, thyroid capsule involvement, multifocal or unifocal tumor, extrathyroidal proliferation, marginal status, and necrosis. Data were obtained and compared in the two groups with SPSS version 22.0 software.

Results

Based on the postoperative pathology reports, 50 (56.2%) PTC patients with Hashimoto thyroiditis were compared against 39 PTC patients without Hashimoto thyroiditis. No significant difference was found between the two groups regarding tumor invasion factors such as multifocality, lymphovascular invasion, marginal invasion, extrathyroidal invasion, capsular invasion, and necrosis.

Conclusion

HT could not be mentioned as an aggravating factor of PTC invasion based on the invasion factors evaluated in pathology specimens.
Literature
1.
2.
Aschebrook-Kilfoy B, Schechter RB, Shih Y-CT, Kaplan EL, Chiu BC-H, Angelos P, Grogan RH. The clinical and economic burden of a sustained increase in thyroid cancer incidence. Cancer Epidemiol Prev Biomarkers. 2013;22(7):1252–9.CrossRef
3.
Sosa JA, Udelsman R. Papillary thyroid cancer. Surg Oncol Clin. 2006;15(3):585–601.CrossRef
4.
Kloos RT. Papillary thyroid cancer: medical management and follow-up. Curr Treat Options Oncol. 2005;6(4):323–38.CrossRefPubMed
5.
Sampson E, Brierley JD, Le LW, Rotstein L, Tsang RW. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2007;110(7):1451–6.CrossRef
6.
7.
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M. 2015 american thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.CrossRefPubMedPubMedCentral
8.
Haddad RI, Nasr C, Bischoff L, Busaidy NL, Byrd D, Callender G, Dickson P, Duh Q-Y, Ehya H, Goldner W. NCCN guidelines insights: thyroid carcinoma, version 2.2018. J Natl Compr Canc Netw. 2018;16(12):1429–40.CrossRefPubMed
9.
Craig SJ, Bysice AM, Nakoneshny SC, Pasieka JL, Chandarana SP. The identification of intraoperative risk factors can reduce, but not exclude, the need for completion thyroidectomy in low-risk papillary thyroid cancer patients. Thyroid. 2020;30(2):222–8.CrossRefPubMedPubMedCentral
10.
Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295(18):2164–7.CrossRefPubMed
11.
Burgess JR, Tucker P. Incidence trends for papillary thyroid carcinoma and their correlation with thyroid surgery and thyroid fine-needle aspirate cytology. Thyroid. 2006;16(1):47–53.CrossRefPubMed
12.
DAILEY ME, LINDSAY S, SKAHEN R. Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA archives of surgery. 1955;70(2):291–7.CrossRefPubMed
13.
Mazokopakis EE, Papadakis JA, Papadomanolaki MG, Batistakis AG, Giannakopoulos TG, Protopapadakis EE, Ganotakis ES. Effects of 12 months treatment with L-selenomethionine on serum anti-TPO levels in patients with Hashimoto’s thyroiditis. Thyroid. 2007;17(7):609–12.CrossRefPubMed
14.
Bossowski A, Otto-Buczkowska E. Schorzenia tarczycy o podłożu autoimmunologicznym.[W:] Pediatria–co nowego.Pod redakcją Ewy Otto-Buczkowskiej2007:108–120.
15.
Fallahi P, Ferrari SM, Ruffilli I, Elia G, Biricotti M, Vita R, Benvenga S, Antonelli A. The association of other autoimmune diseases in patients with autoimmune thyroiditis: review of the literature and report of a large series of patients. Autoimmun rev. 2016;15(12):1125–8.CrossRefPubMed
16.
Fink H, Hintze G. Autoimmune thyroiditis (Hashimoto’s thyroiditis): current diagnostics and therapy. Medizinische Klinik (Munich Germany: 1983). 2010;105(7):485–93.CrossRefPubMed
17.
Wang Y, Wang W. Increasing incidence of thyroid cancer in Shanghai, China, 1983–2007. Asia Pac J Public Health. 2015;27(2):NP223–9.CrossRefPubMed
18.
Franks AL, Slansky JE. Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer. Anticancer Res. 2012;32(4):1119–36.PubMedPubMedCentral
19.
Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? The lancet. 2001;357(9255):539–45.CrossRef
20.
Chen Y-K, Lin C, Cheng FT, Sung F, Kao C. Cancer risk in patients with Hashimoto’s thyroiditis: a nationwide cohort study. Br J Cancer. 2013;109(9):2496–501.CrossRefPubMedPubMedCentral
21.
Moon S, Chung HS, Yu JM, Yoo HJ, Park JH, Kim DS, Park YJ. Associations between Hashimoto thyroiditis and clinical outcomes of papillary thyroid cancer: a meta-analysis of observational studies. Endocrinol metabolism. 2018;33(4):473–84.CrossRef
22.
Dvorkin S, Robenshtok E, Hirsch D, Strenov Y, Shimon I, Benbassat CA. Differentiated thyroid cancer is associated with less aggressive disease and better outcome in patients with coexisting Hashimotos thyroiditis. J Clin Endocrinol Metabolism. 2013;98(6):2409–14.CrossRef
23.
Randolph GW. Surgery of the thyroid and parathyroid glands e-book. Elsevier Health Sciences; 2020.
24.
25.
Lloyd RV. Endocrine Pathology:: Differential diagnosis and molecular advances. Springer Science & Business Media; 2010.
26.
Edition S, Edge S, Byrd D. AJCC cancer staging manual. AJCC cancer staging manual 2017.
27.
Anil C, Goksel S, Gursoy A. Hashimoto’s thyroiditis is not associated with increased risk of thyroid cancer in patients with thyroid nodules: a single-center prospective study. Thyroid. 2010;20(6):601–6.CrossRefPubMed
28.
Randolph GW, Duh Q-Y, Heller KS, LiVolsi VA, Mandel SJ, Steward DL, Tufano RP, Tuttle ftATASACsToTCNS R. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid. 2012;22(11):1144–52.CrossRefPubMed
29.
Cipolla C, Sandonato L, Graceffa G, Fricano S, Torcivia A, Vieni S, Latteri S, Latteri MA. Hashimoto thyroiditis coexistent with papillary thyroid carcinoma. Am Surg. 2005;71(10):874–8.CrossRefPubMed
30.
Jung K-W, Won Y-J, Kong H-J, Oh C-M, Cho H, Lee DH, Lee KH. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res treatment: official J Korean Cancer Association. 2015;47(2):127.CrossRef
31.
Liang J, Zeng W, Fang F, Yu T, Zhao Y, Fan X, Guo N, Gao X. Clinical analysis of Hashimoto thyroiditis coexistent with papillary thyroid cancer in 1392 patients. Acta Otorhinolaryngol Ital. 2017;37(5):393.CrossRefPubMedPubMedCentral
32.
Lee J-H, Kim Y, Choi J-W, Kim Y-S. The association between papillary thyroid carcinoma and histologically proven Hashimoto’s thyroiditis: a meta-analysis. Eur J Endocrinol. 2013;168(3):343–9.CrossRefPubMed
33.
Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncol (Williston Park NY). 2002;16(2):217–26. 229; discussion 230.
34.
Zhu F, Shen YB, Li FQ, Fang Y, Hu L, Wu YJ. The effects of Hashimoto thyroiditis on lymph node metastases in unifocal and multifocal papillary thyroid carcinoma: a retrospective Chinese cohort study.Medicine2016, 95(6).
35.
Zhang L, Li H, Ji Q-h, Zhu Y-x, Wang Z-y, Wang Y, Huang C-p, Shen Q, Li D-s, Wu Y. The clinical features of papillary thyroid cancer in Hashimoto’s thyroiditis patients from an area with a high prevalence of Hashimoto’s disease. BMC Cancer. 2012;12(1):1–8.CrossRef
36.
Zhang Y, Dai J, Wu T, Yang N, Yin Z. The study of the coexistence of Hashimoto’s thyroiditis with papillary thyroid carcinoma. J Cancer Res Clin Oncol. 2014;140(6):1021–6.CrossRefPubMed
37.
Dong S, Xie X-J, Xia Q, Wu Y-J. Indicators of multifocality in papillary thyroid carcinoma concurrent with Hashimoto’s thyroiditis. Am J cancer Res. 2019;9(8):1786.PubMedPubMedCentral
Metadata
Title
The evaluation of locoregional tumoral involvement in the cooccurrence of hashimoto thyroiditis with papillary thyroid cancer: a case controlled study
Authors
Shirzad Nasiri
Seyed Mostafa Meshkati Yazd
Mahsa Gholami
Sepehr Shahriarirad
Sina Sharghi
Reza Shahriarirad
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2023
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-023-01322-5

Other articles of this Issue 1/2023

BMC Endocrine Disorders 1/2023 Go to the issue

Research article

Retinal microvascular changes in diabetic patients with diabetic nephropathy

Research

Thyroid function, glycemic control, and diabetic nephropathy in patients with type 2 diabetes over 24 months: prospective observational study

Research

Systematic review of the effect of caffeine therapy effect on cardiometabolic markers in rat models of the metabolic syndrome

Research

Clinical observation of menopause hormone therapy in postmenopausal women with euthyroid and mild subclinical hypothyroidism

Case Report

Atypical presentations of primary acquired hypothyroidism

Research

Association between metabolic syndrome and stroke: a population based cohort study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits